Work

Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

Year: 2025

Type: article

Study design: Observational Study

Source: European Urology Oncology

DOI: 10.1016/j.euo.2025.06.004

Authors: Miguel Muniz, Oliver Sartor, Jacob J. Orme, Regina M. Koch, Zachary Scharf, Elisabeth I. Heath, Jabra G. Zarka, Adam M. Kase, Irbaz B. Riaz, Jack R. Andrews, Matthew P. Thorpe, A. Tuba Kendi, Gokce Belge Bilgin, Geoffrey B. Johnson, Eugene D. Kwon, Daniel S. Childs

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Mayo Clinic in Arizona, Mayo Clinic Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Prostate Cancer Foundation, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Exelixis, Clovis Oncology, Five Prime Therapeutics, Mirati Therapeutics, Seagen, Eisai, Siemens Healthineers, National Institutes of Health, Pharmacyclics, Janssen Biotech, National Center for Advancing Translational Sciences, Daiichi Sankyo Europe

Award: Mayo Clinic Center for Clinical and Translational Science (CCaTS)

OpenAlex ID: W4412891796

FWCI: 3.598

Cites: 24

Cited by: 6

Related to: 10